{"success":true,"data":{"pressRelease":{"id":"12037","rtpr_id":"nGNX1jn029","ticker":"SLNO","exchange":"NASDAQ","all_tickers":["SLNO"],"title":"SOLENO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO","author":"Globe Newswire","published_at":"2026-04-29T01:51:54.088Z","article_body":"NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\ncommon stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26,\n2025 and November 4, 2025, both dates inclusive (the “Class Period”), of\nthe important May 5, 2026 lead plaintiff deadline.\n\nSO WHAT: If you purchased Soleno common stock during the Class Period you may\nbe entitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the Soleno class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than May 5, 2026. A\nlead plaintiff is a representative party acting on behalf of other class\nmembers in directing the litigation.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar.\nMany of the firm’s attorneys have been recognized by Lawdragon and Super\nLawyers.\n\nDETAILS OF THE CASE: According to the lawsuit, defendants made false and/or\nmisleading statements and/or failed to disclose that: (1) the Soleno Phase 3\nclinical trial program for diazoxide choline extended-release tablets\n(“DCCR”) had systematically downplayed, misrepresented, and/or concealed\nsignificant evidence of safety concerns potentially related to the\nadministration of DCCR, including issues related to excess fluid retention in\nclinical trial participants; (2) as a result, the administration of DCCR to\ntreat hyperphagia in individuals with Prader-Willi syndrome (“PWS”) posed\nmaterially greater safety risks than disclosed by Soleno or its executives;\nand (3) as a result, DCCR had materially lower commercial viability and\nundisclosed risks related to the likelihood of significant and widespread\nadverse events after its commercial launch, including risks related to patient\ndiscontinuation rates, lower patient adoption, prescriber reluctance, adverse\nregulatory action, and potential reputational and legal fallout. When the true\ndetails entered the market, the lawsuit claims that investors suffered\ndamages.\n\nTo join the Soleno class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor’s ability to share in any potential future recovery is\nnot dependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n        Laurence Rosen, Esq.\n        Phillip Kim, Esq.\n        The Rosen Law Firm, P.A.\n        275 Madison Avenue, 40th Floor\n        New York, NY 10016\n        Tel: (212) 686-1060\n        Toll Free: (866) 767-3653\n        Fax: (212) 202-3827\n        case@rosenlegal.com\n        www.rosenlegal.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/745335af-3a3a-4fb5-84c0-fdedc9adf092)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1jn029","title":"SOLENO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO","author":"Globe Newswire","ticker":"SLNO","created":"2026-04-29T01:51:54.088Z","tickers":["SLNO"],"exchange":"NASDAQ","article_body":"NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\ncommon stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26,\n2025 and November 4, 2025, both dates inclusive (the “Class Period”), of\nthe important May 5, 2026 lead plaintiff deadline.\n\nSO WHAT: If you purchased Soleno common stock during the Class Period you may\nbe entitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the Soleno class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than May 5, 2026. A\nlead plaintiff is a representative party acting on behalf of other class\nmembers in directing the litigation.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar.\nMany of the firm’s attorneys have been recognized by Lawdragon and Super\nLawyers.\n\nDETAILS OF THE CASE: According to the lawsuit, defendants made false and/or\nmisleading statements and/or failed to disclose that: (1) the Soleno Phase 3\nclinical trial program for diazoxide choline extended-release tablets\n(“DCCR”) had systematically downplayed, misrepresented, and/or concealed\nsignificant evidence of safety concerns potentially related to the\nadministration of DCCR, including issues related to excess fluid retention in\nclinical trial participants; (2) as a result, the administration of DCCR to\ntreat hyperphagia in individuals with Prader-Willi syndrome (“PWS”) posed\nmaterially greater safety risks than disclosed by Soleno or its executives;\nand (3) as a result, DCCR had materially lower commercial viability and\nundisclosed risks related to the likelihood of significant and widespread\nadverse events after its commercial launch, including risks related to patient\ndiscontinuation rates, lower patient adoption, prescriber reluctance, adverse\nregulatory action, and potential reputational and legal fallout. When the true\ndetails entered the market, the lawsuit claims that investors suffered\ndamages.\n\nTo join the Soleno class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor’s ability to share in any potential future recovery is\nnot dependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n        Laurence Rosen, Esq.\n        Phillip Kim, Esq.\n        The Rosen Law Firm, P.A.\n        275 Madison Avenue, 40th Floor\n        New York, NY 10016\n        Tel: (212) 686-1060\n        Toll Free: (866) 767-3653\n        Fax: (212) 202-3827\n        case@rosenlegal.com\n        www.rosenlegal.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/745335af-3a3a-4fb5-84c0-fdedc9adf092)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-29T01:51:54.137439606Z","server_sent_at_ms":1777427514137},"received_at":"2026-04-29T01:51:54.190Z","source_url":"https://www.globenewswire.com/news-release/2026/04/09/3271477/673/en/rosen-a-leading-investor-rights-law-firm-encourages-soleno-therapeutics-inc-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline-in-securities-class-.html"},"analysis":{"id":"9353","press_release_id":"12037","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Allegations of concealed safety data regarding Phase 3 asset DCCR","Class action alleges misrepresentation of risks related to fluid retention"],"eventType":"legal_litigation","narrative":"Rosen Law Firm announced a May 5, 2026 deadline for investors to serve as lead plaintiff in a class action lawsuit against Soleno Therapeutics.\n\nThe lawsuit alleges the company made false statements regarding its Phase 3 clinical trial for DCCR, specifically concealing significant safety concerns related to excess fluid retention.\n\nComplaints argue that these undisclosed risks materially impact the drug's commercial viability and increase the likelihood of adverse regulatory action.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Class action alleges Soleno concealed safety data for lead drug DCCR."},"keyFigures":{"drugName":"DCCR (diazoxide choline extended-release)","phaseOfTrial":"Phase 3","customDimensions":{"class_period_end":"November 4, 2025","class_period_start":"March 26, 2025","lead_plaintiff_deadline":"May 5, 2026"}},"quotedText":"the Soleno Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”) had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR","namedEntities":{"people":[{"name":"Phillip Kim","role":"Attorney"},{"name":"Laurence Rosen","role":"Founding Partner"}],"products":["DCCR","diazoxide choline extended-release"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO"},{"name":"Rosen Law Firm","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The filing of a securities class action alleging the concealment of critical safety data regarding the company's lead Phase 3 asset is a material threat to credibility and stock price, though it remains an allegation at this stage."},"tickerRelevance":{"others":[],"primary":"SLNO"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"legal/allegation high","sectorWeight":"biotech"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Rosen Law Firm announced a May 5, 2026 deadline for investors to serve as lead plaintiff in a class action lawsuit against Soleno Therapeutics.\n\nThe lawsuit alleges the company made false statements regarding its Phase 3 clinical trial for DCCR, specifically concealing significant safety concerns related to excess fluid retention.\n\nComplaints argue that these undisclosed risks materially impact the drug's commercial viability and increase the likelihood of adverse regulatory action.","key_figures":{"drugName":"DCCR (diazoxide choline extended-release)","phaseOfTrial":"Phase 3","customDimensions":{"class_period_end":"November 4, 2025","class_period_start":"March 26, 2025","lead_plaintiff_deadline":"May 5, 2026"}},"named_entities":{"people":[{"name":"Phillip Kim","role":"Attorney"},{"name":"Laurence Rosen","role":"Founding Partner"}],"products":["DCCR","diazoxide choline extended-release"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO"},{"name":"Rosen Law Firm","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-29T01:52:59.506Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"legal/allegation high","sectorWeight":"biotech"}},"durationMs":64389,"modelName":"glm-4.7"}}